Your search for ‘Spruson & Ferguson’ returned 1,285 results

This case marks the extension of China's judicial protection of IP to digital worlds.

The new act, new guidelines and regulations mark a brand-new landscape of trademark filing and registration in Malaysia.

This is a significant result for registered rights owners and for the law of trade marks in Australia, affirming the protection afforded to registered trade mark holders against concurrent users who cannot demonstrate...

Discusses The Power of Hydrogen report including significant findings, federal government incentives, where Australia fits etc.

In the recent case of Ajinomoto Co Inc v Nutrasweet Australia Pty Ltd [2008] FCAFC 34, the Full Federal Court considered the construction of section 7(3) of the Patents Act 1990 (Cth), which defines the prior art base for the purposes of assessing inventive step.

Can medical procedures and tests be patented in the US?

Patents around the world generally have 20 year terms, calculated from the filing date for convention application.

There can be two businesses with identical trade marks but only one is able to register that mark as a business name.

Grants to reimburse up to 50% of overseas intellectual property legal and registration fees are now available under the EMDG.

The Full Federal Court ruled that patent term extensions apply only to active pharmaceutical ingredients, not formulations, putting formulation-based extensions at risk.

Recent decision confirms that post-filing data can assist in overcoming s40 objections provided the data is confirmatory in nature.

Brand names are important business assets to be carefully selected, built and managed, often through brand licensing.

Reputation may be considered as a Surrounding Circumstance when determining whether marks are Deceptively Similar.

Examines some of the key issues dealt with by the Federal Court in recent patent law cases.

Results of the Senate Legal and Constitutional Affairs Legislation Committee Report into Gene Patents.

The High Court affirmed the Full Federal Court's decision that AstraZeneca's low dose rosuvastatin patent was obvious.

Whether a name is being used as a style name or sub-brand will depend upon the specific circumstances of each case.